Zobrazeno 1 - 5
of 5
pro vyhledávání: '"MP Carmona Oyaga"'
Autor:
G Miron Elorriaga, Y Viseda Torrellas, M Palacios Filardo, M Cardenas Sierra, FJ Goikolea Ugarte, A Martin Torrente, L Torio Alvarez, O Ibarra Barrueta, PR Gemio Zumalave, MP Carmona Oyaga, A Gomez De Segura Sarobe
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ab7ba194797c543e2e7efa5c228be67
https://doi.org/10.1136/ejhpharm-2023-eahp.454
https://doi.org/10.1136/ejhpharm-2023-eahp.454
Autor:
P Pascual Gonzalez, MJ Gayan Lera, L Lombera Saez, D García Echeverría, J Landa Alberdi, MP Carmona Oyaga, T Gonzalez Fernandez, I Aldalur Uranga, A Zurutuza Lopez, MP Bachiller Cacho
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Vancomycin is a glucopeptide antibiotic widely used to treat Gram positive related infections. It is well known for its nefrotoxic and ototoxic profile, but neutropaenia and thrombocytopaenia are not so well described. Purpose The aim of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d0d1da0d5820be91cd522cdf5c00c47
https://doi.org/10.1136/ejhpharm-2019-eahpconf.209
https://doi.org/10.1136/ejhpharm-2019-eahpconf.209
Autor:
J Landa Alberdi, L Lombera Saez, MP Carmona Oyaga, LM Mendarte Barrenechea, MJ Gayan Lera, G Lopez Arzoz, Mauelon Echeverria, A Zurutuza Lopez, MP Bachiller Cacho, JA Iribarren Loyarte
Publikováno v:
Section 1: Introductory Statements and Governance.
Background Following a request by the Central Management Organisation of our Health System (HS), a decision was made to change from a patented drug of three active principals, emtricitabine/tenofovir-disopropilo/rilpivirine (FTC/TDF/RPV) to two drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84b0c6339a4d52742b097d5a02441d52
https://doi.org/10.1136/ejhpharm-2019-eahpconf.5
https://doi.org/10.1136/ejhpharm-2019-eahpconf.5
Autor:
MJ Gayan Lera, L Lombera Saez, MP Bachiller Cacho, MP Carmona Oyaga, I Aguirre Zubia, MA Aranguren Redondo, M Ercilla Liceaga, A Lizardi Mutuberria, L Leunda Eizmendi, M Ripa Ciaurriz
Publikováno v:
European Journal of Hospital Pharmacy. 22:A67.3-A68
Background A drug adjustment programme for patients with renal disease was started in 2013 in our hospital. In this system, information from the electronic prescription programme is linked (using an Access application) with information sent by the la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b31622ed32ff785401bf3f16e9745cd
https://doi.org/10.1136/ejhpharm-2015-000639.161
https://doi.org/10.1136/ejhpharm-2015-000639.161
Autor:
A Lizardi Mutuaberria, M Umerez Igartua, M Barral Juez, MP Carmona Oyaga, J Barral Juez, A Asensio Bermejo, P Pascual Gonzalez, G Lopez Arzoz, G Lizeaga Cundin, MP Bachiller Cacho
Publikováno v:
European Journal of Hospital Pharmacy. 21:A35.1-A35
Background Oral chemotherapy against metastatic or advanced renal-cell carcinoma (mRCC) is currently benefiting from a wide range of possibilities. Purpose To analyse the effectiveness of the actual therapy for the treatment of the mRCC in real condi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::316cfa0da01882468fdc58566dd3626f
https://doi.org/10.1136/ejhpharm-2013-000436.84
https://doi.org/10.1136/ejhpharm-2013-000436.84